

1 **The effect of antidepressants on severity of COVID-19 in hospitalized patients:**
2 **A systematic review and meta-analysis**

3
4
5 Hosein Nakhaee¹, Reza Bayati^{1†}, Mohammad Rahmanian^{1†}, Amir Ghaffari Jolfayi¹, Moein
6 Zangiabadian^{2*}, Sakineh Rakhshanderou^{3*}

7
8 ¹Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences,
9 Tehran, Iran

10
11 ²Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical
12 Sciences, Tehran, Iran

13
14 ³Environmental and Occupational Hazards Control Research Center, School of Public Health, Shahid
15 Beheshti University of Medical Sciences, Tehran, Iran

16
17
18
19 [†] **These authors contributed equally**

20
21
22
23 ***Correspondence:**

24
25 Moein Zangiabadian
26 Zangiabadian1998@gmail.com

27
28 Sakineh Rakhshanderou
29 s_rakhshanderou@sbmu.ac.ir

30
31

32 **Abstract**

33

34 **Introduction:**

35 Clinical depression and the subsequent low immunity is a comorbidity that can act as a risk factor
36 for severity of COVID-19 cases. Antidepressants such as SSRI and SNRI are associated with
37 immune-modulatory effects, which dismiss inflammatory response and reduce lung tissue damage.
38 The current systematic review and meta-analysis aims to evaluate the effect of antidepressant drugs
39 on prognosis and severity of COVID-19 in hospitalized patients.

40

41 **Methods:**

42 A systematic search was carried out in PubMed/Medline, EMBASE, and Scopus up to January
43 16, 2022. The following keywords were used: “COVID-19”, “SARS-CoV-2”, “2019-nCoV”,
44 “SSRI”, “SNRI”, “TCA”, “MAOI”, and “Antidepressant”. The pooled risk ratio (RR) with 95%
45 CI was assessed using a fixed or random-effect model. We considered $P < 0.05$ as statistically
46 significant for publication bias. Data were analyzed by Comprehensive Meta-Analysis software,
47 Version 2.0 (Biostat, Englewood, NJ).

48

49 **Results:**

50 Twelve studies were included in our systematic review. Three of them were experimental with
51 1751, and nine of them were observational with 290,950 participants. Seven out of twelve
52 articles revealed the effect of antidepressants on reducing severity of COVID-19. SSRI
53 medications, including Fluvoxamine, Escitalopram, Fluoxetine, and Paroxetine and also among
54 the SNRI drugs Venlafaxine are also reasonably associated with reduced risk of intubation or
55 death. There were four studies showing no significant effect and one study showing the negative
56 effect of antidepressants on prognosis of covid-19. The meta-analysis on clinical trials showed
57 that fluvoxamine could significantly decrease the severity outcomes of COVID-19 (RR: 0.745;
58 95% CI: 0.580-0.956)

59

60 **Conclusions:** Most of the evidence supports that the use of antidepressant medications, mainly
61 Fluvoxamine may decrease the severity and improve the outcome in hospitalized patients with
62 sars-cov-2. Some studies showed contradictory findings regarding the effects of antidepressants
63 on severity of COVID-19. Further experimental studies should be conducted to clarify the effects
64 of antidepressants on severity of COVID-19.

65 **Keywords:** antidepressants –SSRI- COVID-19 -SARS-CoV-2

66

67

68 Introduction

69
70 After over two years since the first case of the novel coronavirus was detected in December 2019
71 in Wuhan, China, 483 million infected cases and 6.13 million deaths have been reported worldwide
72 up to January 21, 2022 (1). Covid19 is an acute respiratory disease, resulting in progressive
73 respiratory failure, and eventually leading to death. Common symptoms include fever, dry cough,
74 myalgia and fatigue. Severe cases develop dyspnea, hemoptysis, acute respiratory distress
75 syndrome which can result in death. The severity or mortality is higher in older population, with
76 comorbidities such as diabetes, hypertension, cardiovascular diseases and weaker immune
77 functions (2). During the COVID-19 pandemic with strict lockdown measures, psychiatric patients
78 have suffered episodes of anxiety, depression, and stress disorders on higher scales.(3) Clinical
79 depression and the subsequent low immunity can also act as risk factors for severity of COVID-
80 19 cases (4). Patients with clinical depression have lower immunity compared to those of healthy
81 controls. A history of depression is associated with higher risk of infection and also the increased
82 risk remains consistent over time (5). The suggested mechanism of action is fewer circulating
83 CD4⁺ T-cells and reduction in natural killer cell cytotoxic responses of lymphocyte proliferation
84 in elderly patients with clinical depression (6). Treatment of depression as an underlying morbidity
85 could decrease the risk of clinical deterioration of Covid-19 patients. On the other hand,
86 antidepressants such as SNRI and SSRI which are widely used in treatment of psychiatric patients
87 are shown to reduce corona virus infection rates as patients who were receiving these medications
88 were less likely to test positive for COVID-19 (7). Antidepressants are also associated with less
89 severe cases as they significantly reduced the risk of intubation or death in some cohort studies (8,
90 9). Several mechanisms are suggested to justify this finding. Antidepressants could be associated
91 with declined plasma levels of inflammatory cytokines, including IL-10, TNF- α , CCL-2, and IL-
92 6, which are related to COVID-19 severity and mortality (10, 11). Also Some SSRI
93 antidepressants, such as fluvoxamine which is a functional inhibitor of acid sphingomyelinase
94 activity (FIASMA), may prevent the infection of epithelial cells with SARS-CoV-2 (12). In this
95 study we aim to evaluate the effect of antidepressant drugs on prognosis and severity of COVID-
96 19 in hospitalized patients.

98 Method

99
100 This study was conducted and reported in accordance with the Preferred Reporting Items for
101 Systematic Reviews and Meta-Analyses statement (13). The study was registered in the
102 Systematic Review Registration: PROSPERO (pending registration ID: 313272).

103 *Search strategy*

104
105 We searched Pubmed/Medline, Embase and Scopus for clinical studies reporting the effect of
106 anti-depressants on reducing severity of hospitalized patients with covid-19, published up to
107 January 16, 2022. We included clinical trials, cohort and case-control studies that were written
108 in English. We used the following MeSH terms: “‘antidepressive agents’, ‘antidepressive agents,
109 second generation’, ‘antidepressive agents, tricyclic’, ‘monoamine oxidase inhibitors’, ‘serotonin
110 and noradrenaline reuptake inhibitors’, ‘serotonin uptake inhibitors’, ‘COVID-19’ and ‘SARS-
111 CoV-2’” (Table S1&2&3). Keyword searches were done with combinations of the terms “SSRI”,
112 “SNRI”, “TCA”, “MAOI”, “Antidepressant”, “2019 novel coronavirus” and “sars coronavirus

113 2”. Lists of references of selected articles and relevant review articles were hand-searched to
114 identify further studies.

115
116 ***Study Selection***
117

118 The records found through database searching were merged, and the duplicates were removed
119 using EndNote X8 (Thomson Reuters, Toronto, ON, Canada). Two reviewers independently
120 screened the records by title/abstract and full text to exclude those unrelated to the study
121 objectives. Any disagreements were resolved by the lead investigator. Included studies met the
122 following criteria: (i) patients were diagnosed with COVID-19 based on the WHO criteria; (ii)
123 patients were received anti-depressants; and (iii) severity predictors (hospitalization due to
124 COVID-19 and/or ARDS and/or need to NIV or mechanical ventilation and/or ICU admission
125 and/or death). Conference abstracts, editorials, reviews, study protocols, molecular or
126 experimental studies on animal models and studies with focusing on infection risk were
127 excluded.

128
129 ***Data extraction***
130

131 Two reviewers designed a data extraction form. These reviewers extracted data from all eligible
132 studies, and differences were resolved by consensus. The following data were extracted: first
133 author name; year of publication; study duration; type of study, country/ies where the research
134 was conducted; demographics (i.e. age, sex); Detection test of COVID-19; anti-depressant type,
135 dosage and frequency; Follow-up time; the definition of case and control; total number of
136 controls and cases, severity indices, mechanism of action of anti-depressants against COVID-19
137 and Possibility of using anti-depressants in COVID-19 treatment.

138
139 ***Quality assessment***
140

141 Two blinded reviewers assessed the quality of the studies using three different assessment tools
142 (checklists): two for observational studies (case controls and cohorts) and one for experimental
143 studies (14). Items such as study population, measure of exposures, confounding factors, extent
144 of outcomes, follow-up data, and statistical analysis were evaluated.

145
146 ***Statistical Analysis***
147

148 The pooled risk ratios (RRs) with 95% CI were assessed using random or fixed-effect models.
149 The fixed-effects model was used because of the low estimated heterogeneity of the true effect
150 sizes. The between-study heterogeneity was assessed by Cochran’s Q and the I² statistic.
151 Publication bias was evaluated statistically by using Egger’s and Begg’s tests as well as the
152 funnel plot ($p < 0.05$ was considered indicative of statistically significant publication bias; funnel
153 plot asymmetry also suggests bias) (15). All analyses were performed using “Comprehensive
154 Meta-Analysis” software, Version 2.0 (Biostat, Englewood, NJ).

155
156 **Results**
157

158 The selection process of articles is shown in Figure 1. Twelve articles were included and
159 classified into the followings: six cohort studies (8, 16-20), three case-control studies (21-23) and
160 three clinical trials (24-26). There were 872 cases and 879 controls in clinical trials, 15950 cases

161 and 96638 controls in the cohort studies and 97,844 cases and 80518 controls in the case-control
162 studies with the total population of 292701 in the whole studies (114666 cases and 178035
163 controls). Four studies were conducted in USA and other studies were designed in France,
164 Turkey, Brazil, Hungary, Israel, Croatia, Scotland and Italy. The duration of studies, detection
165 test of COVID-19 and other study characteristics are shown in table 1.

166

167

168

169 *Quality of the included studies*

170

171 The checklists for observational studies (14) showed that the included observational studies had a
172 low risk of bias except Bora et al. study (16). (Table 2 & 3) In contrast, the checklist for
173 experimental studies (14) showed that the included experimental studies had a high risk of bias for
174 randomization, group concealment and participants, treatment delivers and outcome assessors
175 blinding except Lenze et al. study (25). (Table 4)

176

177 *Patient Characteristics*

178

179 According to nine studies (8, 16-18, 21-25), the mean age of total patients was 58.1 years old
180 with 40 and 56.5 years old in case and control groups in eight studies, respectively (8, 17, 18, 20,
181 21, 23-25). 49.6 percent of patients were female according to eleven studies (8, 16-21, 23-26).
182 This number was 52% in case groups and 49.3% in control groups according to nine studies (17-
183 21, 23-26). Cases and controls were matched with age, sex, comorbidities, smoking status, BMI
184 category and etc. The definition of case and control groups and severity outcomes are shown in
185 table 5.

186

187 *Interventions and exposures Characteristics*

188

189 Seven studies (18, 20, 21, 23-26) only used or surveyed SSRIs as anti-depressant in case groups
190 (fluvoxamine in five studies (18, 20, 24-26), fluoxetine in two studies (18, 23) and Escitalopram
191 in one study (21)). In remain five studies (8, 16, 17, 19, 22) different types of SSRIs, SNRIs and
192 TCAs were used or surveyed. Anti-depressant type, dosage, frequency and follow-up time are
193 shown in table 6.

194

195 *Effect of anti-depressants on severity outcomes of COVID-19*

196

197 After adjustment, seven studies (8, 16, 18, 20, 21, 23, 25) showed significant association
198 between anti-depressant use and reducing severity outcomes of COVID-19. On the other hand,
199 five studies (17, 19, 22, 24, 26) presented that either there are not any significant effect for anti-
200 depressants to reduce disease severity or anti-depressants are associated with severe COVID-19
201 in hospitalized patients. In the study that was conducted by Bora et al. (16) anti-depressants were
202 associated with reducing mortality, regardless of the anti-depressant type. Hoertel et al. (8)
203 suggested that antidepressant use (HR:0.56; 95% CI: 0.43–0.73) is significantly and substantially
204 associated with reduced risk of intubation or death, independently of patient characteristics,
205 clinical and biological markers of disease severity, and other psychotropic medications. They
206 found that SSRI (HR:0.51; 95% CI:0.316–0.72) and non-SSRI (HR:0.65; 95% CI, 0.45–0.93)
207 antidepressants, and specifically the SSRIs escitalopram, fluoxetine, and paroxetine, the SNRI

208 venlafaxine and the α 2-antagonist antidepressants mirtazapine are significantly associated with
209 reduced risk of intubation or death. Escitalopram is also effective in reducing severity according
210 to Israel et al. (21) study. Fluoxetine use was associated with an important (70%) decrease
211 of mortality (OR:0.33; 95% CI:0.16–0.68) and threefold survival in fluoxetine group according
212 to Nemeth et al. (23) study. Also another study by Oskotsky et al. (18) showed similar result that
213 fluoxetine could reduce risk of mortality (RR:0.72; 95% CI:0.54-0.97). On the other hand,
214 Rauchman et al. (19) mentioned that prior use of SSRIs or SNRIs did not reduce mortality
215 (OR:0.96; 95% CI:0.79-1.16). McKeigue et al. (22) proposed that TCAs (RR:1.1; 95% CI: 0.94-
216 1.27) and SSRIs (RR:1.18; 95% CI:1.03-1.36) like other anti-depressants (RR: 1.76; 95% CI:1.5-
217 2.07) increase the risk of severe COVID-19 because of their anti-cholinergic effect that is likely
218 to increase risk of pneumonia. However, Fei et al. (17) represented that mortality rate, respiratory
219 failure related to pneumonia and renal failure as a comorbidity within the anti-depressant treated
220 subgroup is not lower than in the other patient of the sample but suggested that anti-depressant
221 treated patient subgroup show high mean age and high size of medical comorbidity. Although, it
222 is shown in this study that ARDS is significantly lower for the anti-depressant treated subgroup
223 so mild significant lower employment of protease inhibitors and endotracheal intubation is
224 needed in this subgroup because of lower level of IL-6 in anti-depressant treated patient that
225 resulted from inhibition function of acid sphingomyelinase induced by antidepressants.

226

227 *Specific effect of fluvoxamine on severity outcomes of COVID-19*

228

229 Four studies have discussed about the relation of using fluvoxamine and COVID-19 severity.
230 One cohort study (20) and three clinical trials (24-26). Lenze et al. (25) represented that patients
231 treated with fluvoxamine, compared with placebo, had a lower likelihood of clinical deterioration
232 over 15 days (absolute difference:8.7% 95% CI:1.8%-16.4%). Also serious adverse events in
233 fluvoxamine group were less than placebo group (1.3% vs 6.9%). They suggested that this effect
234 is because of the influence of fluvoxamine on the S1R-IRE1 pathway and anti-inflammatory
235 (Cytokine reduction) actions resulting from S1R activation. Also according to Seftel et al. (20)
236 study the incidence of subsequent hospitalization was lower in fluvoxamine group (0% vs
237 12.5%) and elevated respiratory rates were improved faster by day 7 in this group so
238 fluvoxamine seems to be promising as early treatment for COVID-19 to prevent clinical
239 deterioration requiring hospitalization and to prevent possible long haul symptoms persisting
240 beyond 2 weeks. On the other hand, Reis et al. (26) suggested that There were no significant
241 differences between fluvoxamine and placebo for viral clearance at day 7 (RR:0.67; 95%
242 CI:0.42–1.06), hospitalizations due to COVID-19 (RR:0.77; 95% CI:0.55–1.05), time to
243 hospitalization (RR:0.79; 95% CI:0.58–1.06), mechanical ventilation (RR:0.77; CI:0.45–1.30),
244 time on mechanical ventilation (RR:1.03; 95% CI: 0.64–1.67), death (RR:0.69; 95% CI:0.36–
245 1.27) and time to death (RR:0.80; 95%CI:0.43–1.51). However, according to Calusic et al. (24)
246 study, there was no statistically significant differences between groups were observed regarding
247 the number of days on ventilator support, duration of ICU or total hospital stay. But overall
248 mortality was lower in the fluvoxamine group (HR: 0.58; 95% CI: 0.36–0.94). Although only
249 mortality in women were significantly reduced in fluvoxamine group (HR: 0.40; 95% CI: 0.16–
250 0.99) and there were no significant differences in men mortality (HR: 0.69; 95% CI: 0.39–1.24).

251

252 *Statistical focus on fluvoxamine*

253
254 The meta-analysis on clinical trials showed that fluvoxamine could significantly decrease the
255 severity outcomes of COVID-19 (RR: 0.745; 95% CI: 0.580-0.956) (figure 2). There was no
256 evidence of publication bias ($p > 0.05$) (figure 3).

257
258
259

260 **Discussion**

261
262 Our systematic review study included cohort, case-control, and clinical trials and showed
263 contradictory findings regarding the effect of antidepressant drugs on severity and mortality in
264 covid-19 patients. Although various subgroups of antidepressants mainly reduce the risk of ARDS
265 and mortality in hospitalized covid-19 patients compared to control groups, some studies reported
266 no difference between case and control groups. On the other hand, one study proposed that
267 antidepressants such as SSRIs and TCAs increase the risk of severe COVID-19 due to their
268 anticholinergic effect that is likely to cause pneumonia.

269 Our meta-analysis on clinical trials also demonstrated that fluvoxamine could significantly
270 decrease the severity outcomes of COVID-19 and as Seftel et al. (20) study proposed that it can
271 be a therapeutic choice to prevent clinical deterioration requiring hospitalization for COVID-19
272 patients.

273 It has been proven that patients with clinical depression have lower immunity and thus more
274 vulnerability to infection than healthy controls. (5) The suggested mechanism of action is fewer
275 circulating CD4+ T-cells and reduction in natural killer cell cytotoxic responses of lymphocyte
276 proliferation in elderly patients with clinical depression. There is also an abnormal regulation of
277 the hypothalamus–pituitary–adrenal axis, sympathetic–adrenal–medullary axis, and
278 hypothalamic-pituitary ovarian axis in patients with clinical depression (6). On the other hand,
279 severe cases of COVID-19 infection are associated with an increase in the production of anti-
280 inflammatory cytokines such as IL-6, IL-8, IL-10, and proliferation of CD8+ cytotoxic T-cells
281 derived from CD4+ T-cells, which act in neutralizing the virus and inflammation of the lung (27).
282 Thus it is justified to consider clinical depression and the subsequent low immunity as risk factors
283 for the severity of COVID-19 cases.

284 In covid-19 patients with clinical depression, anti-depression treatment could improve immune
285 responses by neutralizing the comorbidity (28). Still, there are several other mechanisms through
286 which antidepressants might lower the risk of severe outcomes.

287

288 *Inhibition of serotonin transporter*

289 SSRI and SNRIs are shown to have anti-inflammatory effects in both preclinical and clinical
290 studies.(11, 29, 30) this might be owing to serotonin transporter inhibition.(31) Serotonin is
291 involved in anti-inflammatory cytokine production. (32) For example, it can increase the release
292 of the IL-10, which is a potent cytokine with reputable anti-inflammatory assets (33) IL-10 also
293 moderates the levels of TNF- α and IL-6(34) . Which are both responsible for the inflammatory
294 response in covid-19 infection. Serotonin also reduces the production of inflammatory cytokines
295 such as TNF- α and interferon-gamma (IFN- γ) by human blood leucocytes (35, 36). High serotonin
296 transporter expression in the lungs(37) brings up its possible function in lung inflammation.
297 Serotonin inhibits IL-12 and TNF- α release in human alveolar macrophages, but it increases IL-

298 10 production via 5-HT₂ receptors (38). Therefore, SSRIs and SNRIs may influence COVID-19
299 patients' lung function. Considering that other antidepressants with the ability to block serotonin
300 transporters did not show similar beneficial effects for COVID-19 patients, it is unlikely that
301 serotonin transporter inhibition may play a significant role in SSRIs' beneficial effects for COVID-
302 19 patients. However, the anti-inflammatory effects of serotonin transporter inhibition may be a
303 factor for the beneficial effects of SSRIs such as fluoxetine and fluvoxamine (31).

304

305

306

307 *Acid sphingomyelinase (ASM)*

308 Many antidepressants, such as fluoxetine, fluvoxamine, sertraline, paroxetine, and amitriptyline,
309 directly inhibit acid sphingomyelinase activity (11, 39, 40) which is necessary for epithelial cells
310 to uptake SARS-CoV-2 (41). This could explain the findings of Hoertel et al. study (8), although
311 considering that there are other drugs such as chlorpromazine with ASM inhibition activity that
312 didn't show the same protective effects on mortality in COVID-19 patients (42), this mechanism
313 is unlikely a major factor for said effect.

314

315 *Sigma-1 receptor*

316 sigma-1 receptor, an endoplasmic reticulum (ER) protein, is a cellular factor mediating the early
317 steps of viral RNA replication, thus essential for virus replication at the early stage of infection
318 (43, 44). A recent study showed that several compounds for sigma-1 and sigma-2 receptors are
319 active in protein-protein interactions between SARS-CoV-2 and human proteins and could be
320 promising inhibitors for SARS-CoV-2 replication (45).

321 On the other hand, animal studies indicated that some SSRIs, such as fluvoxamine, sertraline,
322 fluoxetine, and citalopram, have a high to moderate affinity for sigma-1 receptors in the rat brain.
323 (45). Binding of sigma-1 receptor agonists (i.e., fluvoxamine and fluoxetine) can result in sigma-
324 1 receptor chaperone activity in the cells (46, 47). Another study demonstrated that binding of
325 fluoxetine to the sigma-1 receptor in the endoplasmic reticulum decreases cytokine activity and
326 enhances survival in preclinical models of sepsis and inflammation (48). Given the crucial role of
327 the chaperone activity by sigma-1 receptor agonist in SARS-CoV-2 replication, it is possible that
328 the SSRIs (i.e., fluvoxamine, fluoxetine, escitalopram) with sigma-1 receptor agonists could be
329 COVID-19 prophylactic drugs (8).

330

331 Another mechanism proposed to explain the anti-inflammatory effects of SSRIs is increasing
332 melatonin levels due to cytochrome P450 enzyme CYP1A2 inhibition by fluvoxamine (49, 50).
333 Melatonin which is naturally synthesized in the pineal gland and immune cells from the amino
334 acid tryptophan, has anti-inflammatory, immunomodulatory, and antioxidant effects and is a
335 therapeutic candidate to treat COVID-19 (51).

336

337

338 Among the articles indicating no significant effect for antidepressants, Fei et al. (17) and Calusic
339 et al. (24) studies were limited by small sample size. Calusic et al. (24) and Reis et al. (26)
340 studies couldn't entirely rule out selection bias. Fei et al. also stated that control group showed
341 higher mean age and high size of medical comorbidities. Patients with antidepressant therapy
342 have worse health conditions and immune responses than general population. This issue can have
343 an impact on prognosis of COVID-19 (17).

344 Another important clinical issue is to either continue or discontinue SSRIs when a COVID-19
345 patient is hospitalized or admitted to an ICU. There is evidence showing adverse ICU outcomes
346 after discontinuation of SSRIs. This is probably due to increased agitation and need for sedation
347 among these patients that can result in respiratory depression (52, 53). SSRI use may sometimes
348 be contraindicated in ICU patients due to ECG changes and abnormal coagulation effects(54). A
349 systematic review regarding the use of antidepressants in Critical Care, suggested that there may
350 be excess morbidity in critically ill SSRI/SNRI users, but whether this is due to chronic effects,
351 ongoing use, or drug withdrawal is unclear (53).

352 Reis et al (26) study suggested the modulatory effect of fluvoxamine on systemic inflammation
353 as lower respiratory tract infections and hospital admissions were reported less frequently in
354 patients in the fluvoxamine group compared to those in the placebo group.

355
356 Finally, efficacy of fluvoxamine in COVID-19 patients could be dependent on the timing of
357 treatment, where increased effectiveness could be achieved if treatment is initiated earlier during
358 SARSCoV-2 infection.

359

360 *Limitations*

361

362 Most of the included articles in this study were not specific about antidepressant drugs and didn't
363 evaluate each drug separately. They mainly studied antidepressants in groups like SSRIs, SNRIs,
364 and TCAs. We reviewed antidepressants but could only arrange a meta-analysis for fluvoxamine
365 which was studied in three clinical trial which two of them had a high risk of bias. Our meta-
366 analysis was limited to a small population of about 2000 persons. We also generally expressed our
367 results about severity and outcome and couldn't arrange a subgroup analysis for each outcome or
368 sex group.

369

370 *Suggestions*

371 As there is strong evidence of the link between antidepressant use and improving outcomes of
372 covid-19, it seems legible to conduct more research on the subject, aiming to find more therapeutic
373 options to treat covid-19. Future studies should focus on antidepressants separately and be more
374 specific about the outcome in different patient groups. We also need to arrange more clinical trials
375 with larger populations to confirm the efficacy of a candidate certainly. SSRIs such as Fluoxetine
376 and Fluvoxamine are supported by stronger evidence and could be favorable options for future
377 research programs.

378

379 **Conclusion**

380

381 Among the studied experiment, seven studies showed anti-depressant ability to reduce the severity
382 of covid-19, and five studies didn't mention any significant effect on it. The covid-19 reducing
383 effect of the mentioned medications can be concluded from the decline in the risk of intubation
384 and death, clinical outcomes, and biological markers demonstrating the disease's severity. Among
385 the SSRI medication, the most common studied drug was fluvoxamine, which has a less
386 subsequent hospitalization rate, less likelihood of 15-day-deterioration, and fewer adverse events
387 than placebo, attributable to the 5-HT_{1A}-IRE1 pathway and anti-inflammatory actions. Other SSRI
388 medications, including Escitalopram, Fluoxetine, and Paroxetine and also among the SNRI drugs
389 Venlafaxine are also reasonably associated with reduced risk of intubation or death. Still, they
390 didn't study as much as fluvoxamine. Although most of the evidence supports the effectiveness

391 hypothesis of anti-depressant drugs, a single study proposed that some anti-depressants can
392 intensify the severity of COVID-19 via anticholinergic effects that induce pneumonia. This issue
393 should be investigated more precisely in future studies.

394
395
396
397
398
399

400 **DATA AVAILABILITY STATEMENT**

401
402
403

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding authors.

404

405 **AUTHOR CONTRIBUTIONS**

406

407 MZ, HN: designed the study. MZ, RB, MR, and AG: performed the search, study selection, and
408 data synthesis. MZ, HN: wrote the first draft of the manuscript. SR: revised the article. All
409 authors contributed to the article and approved the submitted version.

410

411 **CONFLICT OF INTREST:**

412

The mentioned in this article, have no involvement in any organization or entity with any financial interest nor non-financial interest such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter discussed in this article.


413
414
415

416 **ACKNOWLEDGMENTS**

417

418 This study is related to the MPH project From the Department of Public Health, School of Public
419 Health and Safety, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

420



421

422 Figure1. Flow chart of study selection for inclusion in the systematic review and meta-analysis.

423

424 Table 1. Study characteristics
425

First author	Study design	Publication year	country	Study duration	detection test of COVID-19
Lenze et al. (25)	Randomized Clinical Trial	2020	USA	April 10, 2020, to August 5, 2020	PCR
Reis et al. (26)	Randomized Clinical Trial	2021	Brazil	June 2, 2020 to Aug 5, 2021	RT-PCR
Calusic et al. (24)	cohort trial	2021	Croatia	April and May 2021,	PCR
Israel et al. (21)	case-control	2021	Israel	November 30, 2020 to December 31, 2020.	RT-PCR
McKeigue et al. (22)	case-control	2021	Scotland	June 6, 2020 to June 14, 2020	N/R
Nemeth et al. (23)	case-control	2021	Hungary	March 17, 2021 to April 22, 2021	antigen or polymerase chain reaction test
Rauchman et al. (19)	retrospective cohort	2021	USA	March 2020 to March 2021	N/R
Hoertel et al. (8)	retrospective cohort	2021	France	January 24, 2020 to April 1, 2020	RT-PCR
FEI et al. (17)	Prospective Cohort	2021	Italy	N/R	N/R
Oskotsky et al. (18)	retrospective cohort	2020	USA	January to September 2020	laboratory test for SARS-CoV-2 (nucleic acid amplification tests and immunoassays) and/or by ICD-10 (for COVID-19 confirmed by laboratory testing)
Seftel et al. (20)	Prospective Cohort	2021	USA	November–December 2020	PCR
Bora et al. (16)	retrospective cohort	2021	Turkey	October 1, 2020 to January 1, 2021	the ICD-10 classification confirmed by the test results

426
427 **ABBREVIATIONS**
428 PCR: polymerase chain reaction/ RT-PCR: reverse transcription polymerase chain reaction/ ICD 10:
429 International Statistical Classification of Diseases and Related Health Problems, Tenth Revision/ N/R: not reported
430
431
432

433

author	1	2	3	4	5	6	7	8	9	10	11
Rauchman	yes	yes	yes	no	no	yes	yes	yes	yes	yes	yes
Hoertel	yes	yes	yes	no	yes	yes	yes	yes	yes	no	yes
FEI	yes	yes	yes	no	no	yes	yes	yes	yes	yes	yes
Oskotsky	yes	yes	yes	no	yes	unclear	yes	yes	yes	yes	yes
Seftel	yes	yes	yes	no	yes	yes	yes	no	yes	yes	yes
Bora	yes	yes	yes	no	no	yes	yes	unclear	unclear	unclear	yes

434 Table 2. Quality assessment of cohort studies

435

- 436 1. Were the two groups similar and recruited from the same population?
 437 2. Were the exposures measured similarly to assign people to both exposed and unexposed groups?
 438 3. Was the exposure measured in a valid and reliable way?
 439 4. Were confounding factors identified?
 440 5. Were strategies to deal with confounding factors stated?
 441 6. Were the groups/participants free of the outcome at the start of the study?
 442 7. Were the outcomes measured in a valid and reliable way?
 443 8. Was the follow-up time reported and sufficient to be long enough for outcomes to occur?
 444 9. Was follow-up complete, and, if not, were the reasons to loss to follow-up described and explored?
 445 10. Were strategies to address incomplete follow-up utilized?
 446 11. Was appropriate statistical analysis used

447 Table 3. Quality assessment of case-control studies

author	1	2	3	4	5	6	7	8	9	10
Israel (Cohort1)	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes
Israel (Cohort2)	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes
McKeigue	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes
Nemeth	yes	yes	yes	yes	yes	no	no	yes	yes	yes

448

1. Were the groups comparable other than the presence of disease in cases or the absence of disease in controls?
2. Were cases and controls matched appropriately?
3. Were the same criteria used for identification of cases and controls?
4. Was exposure measured in a standard, valid and reliable way?
5. Was exposure measured in the same way for cases and controls?
6. Were confounding factors identified?
7. Were strategies to deal with confounding factors stated?
8. Were outcomes assessed in a standard, valid and reliable way for cases and controls?
9. Was the exposure period of interest long enough to be meaningful?
10. Was appropriate statistical analysis used?

449

450 Table 4. Quality assessment of the experimental studies

author	1	2	3	4	5	6	7	8	9	10	11	12	13
Lenze	yes	yes	yes	Yes	yes	yes	yes	yes	yes	yes	yes	yes	yes
Calusic	unclear	unclear	yes	Unclear	unclear	unclear	yes	yes	yes	yes	yes	yes	yes
Reis	yes	yes	yes	Unclear	unclear	unclear	yes	yes	yes	yes	yes	yes	yes

- 451
- 452 1. Was true randomization used for assignment of participants to treatment groups?
- 453 2. Was allocation to treatment groups concealed?
- 454 3. Were treatment groups similar at baseline?
- 455 4. Were participants blind to treatment assignment?
- 456 5. Were those delivering treatment blind to treatment assignment?
- 457 6. Were outcome assessors blind to treatment assignment?
- 458 7. Were treatment groups treated identically other than the intervention of interest?
- 459 8. Was follow-up complete, and, if not, were differences between groups in terms of their follow-up adequately described and
- 460 analyzed?
- 461 9. Were participants analyzed in the groups to which they were randomized?
- 462 10. Were outcomes measured in the same way for treatment groups?
- 463 11. Were outcomes measured in a reliable way?
- 464 12. Was appropriate statistical analysis used?
- 465 13. Was the trial design appropriate and were any deviations from the standard randomized controlled trial design accounted for
- 466 in the conduct and analysis of the trial?
- 467

468

469 Table 5. Patient characteristics

First author	Age		Gender (F/M %)		matching	Case definition	Control definition	Severity indices
	case	control	case	Control				
Lenze et al. (25)	Mean:46 46		71.7/28.3 70/30	Control 74/26	1:1 Age, sex	Adults with SARS CoV-2 infection who received Fluvoxamine and were symptomatic within 7 days of the first dose of study medication	Adults with SARS CoV-2 infection who received placebo capsules and were symptomatic within 7 days of the first dose of study medication	oxygen saturation <92% plus supplemental oxygen needed and hospitalization related to dyspnea or hypoxia and/or ventilator support needed for ≥3 days
Reis et al. (26)	Median:50		57.5/42.5 55/45	60/40	1:1 BMI, Age, co-morbidities	patients were allocated to fluvoxamine	patients were allocated to placebo	Hospitalized for COVID-19, need to mechanical ventilation and/or mortality
Calusic et al. (24)	Mean:65.7 65.6	65.9	33.3/66.7 33/67	33/67	1:1 Age, sex, co-morbidities, vaccination status, disease severity	patients over the age of 18 with positive SARS-CoV-2 PCR test and acute clinical condition consistent with COVID-19 requiring ICU admission who received fluvoxamine + standard therapy	patients over the age of 18 with positive SARS-CoV-2 PCR test and acute clinical condition consistent with COVID-19 requiring ICU admission who received standard therapy	Days of hospital stay, Days of ICU stay, Days on ventilator support and/or mortality
Israel et al. (21) Group 1	Mean: 64.7 64.6	64.8	49.9/50.1 50/50	50/50	1:5 Age, sex, co-morbidities, BMI, smoking status	Hospitalized COVID-19 patients	patients were chosen among the general population	overall risk for hospitalization due to COVID-19
Israel et al. (21) Group 2	Mean: 65.7 65.7	65.7	48.6/51.4 49/51	49/51	1:2 Age, sex, co-morbidities, BMI, smoking status	Hospitalized COVID-19 patients	patients who had a positive test for SARS-CoV-2 but had not been hospitalized	Risk for COVID-19 hospitalization in patients who had a proven infection with the virus.
McKeigue et al. (22)	Mean:61.2		N/R		1:10 sex	A positive nucleic acid test followed by entry to critical care or death within 28 days or a death certificate with COVID-19 as underlying cause.	Controls were alive and had not yet tested positive on the date that the case first tested positive.	entry to critical care and/or mortality

Nemeth et al. (23)	Mean: 66 65 67	54.6/45.4 53/47 44/56	1:1.5 N/R	adult patients hospitalized with moderate or severe COVID-19 pneumonia who received fluoxetine as an adjuvant medication in combination with antiviral drugs	adult patients hospitalized with moderate or severe COVID-19 pneumonia who received antiviral drugs	mortality between hospital days 2 and 28
Rauchman et al. (19)	>=18	45.9/54.1 61/39 44/56	1:10 Age, sex, primary race	adult patients 18 and over admitted with a diagnosis of COVID-19 and on an antidepressant drug during admission	adult patients 18 and over admitted with a diagnosis of COVID-19 and not on an antidepressant drug during admission	mortality
Hoertel et al. (8)	Mean:57.6 73.7 56.8	49.2/50.8	1:14.5 N/R	Patients who receiving any antidepressant during the first 48 h of hospital admission and before the end of the index hospitalization or intubation or death	Patients not receiving any antidepressant during the first 48 h of hospital admission and before the end of the index hospitalization or intubation or death	intubation or death
FEI et al. (17)	Mean:70 80.1 69.1	40.3/59.7 56/44 39/61	1:11 N/R	patient treated with an antidepressant before admission until discharge from hospital	patient not treated with antidepressant	noninvasive ventilation (NIV), intubation, ICU admission, mortality
Oskotsky et al. (18)	Mean:52 63.1 51.6	50.1/49.9 59/41 50/50	1:21 Age, sex, race & ethnicity, co-morbidities	Patients with COVID-19 and a medication order for an SSRI at least once within a period of 10 days before and 7 days after their first recorded COVID-19 diagnosis	patients with COVID-19 and no SSRI orders	mortality
Seftel et al. (20)	Median:42 Mean:44 Mean:43	24.8/75.2 23/77 27/73	1.5:1 Demographic features	patients treated with fluvoxamine for 14 days	patients not treated with fluvoxamine	Hospitalization, ICU care and /or mortality
Bora et al. (16)	Mean:47.6	46.6/53.4	1:9	patients treated by antidepressants with no limit to the types of these medications	patients not treated by antidepressants	mortality

470

471 ABBREVIATIONS

472 BMI: body mass index/ ICU: intensive care unit/ PCR: polymerase chain reaction/ N/R: not reported

473

474

475

476

477

478

479 Table 6. Interventions and exposures Characteristics

First author	Anti-depressant type	Dosage	Frequency	Follow-up time
Lenze et al. (25)	Fluvoxamine	50 mg (in the evening immediately after the baseline assessment and confirmation of eligibility) 100 mg (for 2 days) 100 mg (through day 15 then stopped)	--- twice daily 3 times daily	30 days
Reis et al. (26)	Fluvoxamine	100mg (for 10 days)	twice daily	28days
Calusic et al. (24)	Fluvoxamine	100 mg (for 15 days) 50 mg (After Day15)	3 times daily twice daily	22 days
Israel et al. (21)	Escitalopram	N/R	N/R	35 days
McKeig ue et al. (22)	TCA's & SSRI's & other anti-depressants	N/R	N/R	N/R
Nemeth et al. (23)	Fluoxetine	20 mg	once daily	N/R
Rauchman et al. (19)	Citalopram, Desvenlafaxine, Duloxetine, Escitalopram, Fluoxetine, Paroxetine, Sertraline, Venlafaxine	N/R	N/R	N/R
Hoertel et al. (8)	Citalopram Escitalopram Citalopram or Escitalopram Flouxetine Fluvoxamine Paroxetine Sertraline Vortioxetine Venlafaxine Duloxetine	N/R	N/R	18.4 days
FEI et al. (17)	Sertraline Escitalopram Citalopram Paroxetine Venlafaxine Duloxetine Escitalopram + Venlafaxine	N/R	N/R	3 months
Oskotsky et al. (18)	Fluoxetine Flouxetine or Fluvoxamine SSRI other than Flouxetine or Fluvoxamine	30.2mg/d 29mg/d 30.4mg/d	N/R	8 months
Seftel et al. (20)	Fluvoxamine	50- to 100-mg loading dose 50 mg	--- twice daily	14 days

Bora et al. (16)	Duloxetine, Escitalopram, Fluoxetine, Fluvoxamine, Mirtazapine, Paroxetine, Sertraline, Venlafaxine, tricyclic antidepressants	N/R	N/R	N/R
-------------------------	--	-----	-----	-----


480

481 ABBREVIATIONS

482 SSRI: Selective serotonin re-uptake inhibitors/ TCA: Tricyclic antidepressant

483

484




485

486

487 Figure 2. Pooled RR for clinical trials

488



489

490 Figure 3. the funnel plot of analysis

491

492 References

- 493 1. Organization WH. WHO Coronavirus (COVID-19) Dashboard 2022 [Available from:
494 <https://covid19.who.int/>.
- 495 2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019
496 novel coronavirus in Wuhan, China. *Lancet (London, England)*. 2020;395(10223):497-506.
- 497 3. Hao F, Tan W, Jiang L, Zhang L, Zhao X, Zou Y, et al. Do psychiatric patients experience more
498 psychiatric symptoms during COVID-19 pandemic and lockdown? A case-control study with service and
499 research implications for immunopsychiatry. *Brain, behavior, and immunity*. 2020;87:100-6.
- 500 4. Das A, Halder A, Patil RS, Harshe DG. Susceptibility of clinically depressed patients to COVID-19:
501 Is there a link? *Indian J Psychiatry*. 2021;63(1):112-3.
- 502 5. Andersson NW, Goodwin RD, Okkels N, Gustafsson LN, Taha F, Cole SW, et al. Depression and
503 the risk of severe infections: prospective analyses on a nationwide representative sample. *Int J*
504 *Epidemiol*. 2016;45(1):131-9.
- 505 6. Herbert TB, Cohen S. Depression and immunity: a meta-analytic review. *Psychol Bull*.
506 1993;113(3):472-86.
- 507 7. Clelland CL, Ramiah K, Steinberg L, Clelland JD. Analysis of the impact of antidepressants and
508 other medications on COVID-19 infection risk in a chronic psychiatric in-patient cohort. *BJPsych Open*.
509 2021;8(1):e6.
- 510 8. Hoertel N, Sánchez-Rico M, Vernet R, Beeker N, Jannot AS, Neuraz A, et al. Association between
511 antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19:
512 results from an observational study. *Mol Psychiatry*. 2021;26(9):5199-212.
- 513 9. Díez-Quevedo C, Iglesias-González M, Giralt-López M, Rangil T, Sanagustin D, Moreira M, et al.
514 Mental disorders, psychopharmacological treatments, and mortality in 2150 COVID-19 Spanish
515 inpatients. *Acta Psychiatr Scand*. 2021;143(6):526-34.
- 516 10. Hojyo S, Uchida M, Tanaka K, Hasebe R, Tanaka Y, Murakami M, et al. How COVID-19 induces
517 cytokine storm with high mortality. *Inflammation and Regeneration*. 2020;40(1):37.
- 518 11. Köhler CA, Freitas TH, Stubbs B, Maes M, Solmi M, Veronese N, et al. Peripheral Alterations in
519 Cytokine and Chemokine Levels After Antidepressant Drug Treatment for Major Depressive Disorder:
520 Systematic Review and Meta-Analysis. *Mol Neurobiol*. 2018;55(5):4195-206.
- 521 12. Gulbins E, Palmada M, Reichel M, Lüth A, Böhmer C, Amato D, et al. Acid sphingomyelinase-
522 ceramide system mediates effects of antidepressant drugs. *Nat Med*. 2013;19(7):934-8.
- 523 13. Moher D, Liberati A, Tetzlaff J, Altman DG, Group* P. Preferred reporting items for systematic
524 reviews and meta-analyses: the PRISMA statement. *Annals of internal medicine*. 2009;151(4):264-9.
- 525 14. Institute JB. Critical Appraisal Tools JBIUoA, South Australia; 2021 [Available from:
526 [https://jbi.global/critical-appraisal-tools](https://jbi.global/critical-appraisal-tools;);
- 527 .
- 528 15. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias.
529 *Biometrics*. 1994:1088-101.
- 530 16. Bora ES, Arıkan C, Yurtsever G, Acar H, Delibaş DH, Topal FE. Is it possible that antidepressants
531 protect against COVID-19? *Annals of Clinical and Analytical Medicine*. 2021:991-4.
- 532 17. Fei L, Santarelli G, D'Anna G, Moretti S, Mirossi G, Patti A, et al. Can SSRI/SNRI antidepressants
533 decrease the cytokine storm in the course of COVID-19 pneumonia? *Panminerva medica*. 2021.
- 534 18. Oskotsky T, Marić I, Tang A, Oskotsky B, Wong RJ, Aghaeepour N, et al. Mortality risk among
535 patients with COVID-19 prescribed selective serotonin reuptake inhibitor antidepressants. *JAMA*
536 *network open*. 2021;4(11):e2133090-e.

- 537 19. Rauchman SH, Mendelson SG, Rauchman C, Kasselmann LJ, Pinkhasov A, Reiss AB. Ongoing Use of
538 SSRIs Does Not Alter Outcome in Hospitalized COVID-19 Patients: A Retrospective Analysis. *Journal of*
539 *Clinical Medicine*. 2022;11(1):70.
- 540 20. Seftel D, Boulware DR, editors. Prospective cohort of fluvoxamine for early treatment of
541 coronavirus disease 19. *Open Forum Infectious Diseases*; 2021: Oxford University Press US.
- 542 21. Israel A, Schäffer AA, Cicurel A, Cheng K, Sinha S, Schiff E, et al. Identification of drugs associated
543 with reduced severity of COVID-19—a case-control study in a large population. *Elife*. 2021;10:e68165.
- 544 22. McKeigue PM, Kennedy S, Weir A, Bishop J, McGurnaghan SJ, McAllister D, et al. Relation of
545 severe COVID-19 to polypharmacy and prescribing of psychotropic drugs: the REACT-SCOT case-control
546 study. *BMC medicine*. 2021;19(1):1-11.
- 547 23. Németh ZK, Szûcs A, Vitrai J, Juhász D, Németh JP, Holló A. Fluoxetine use is associated with
548 improved survival of patients with COVID-19 pneumonia: A retrospective case-control study. *Ideggyogy*
549 *Sz*. 2021;74(11-12):389-96.
- 550 24. Calusic M, Marcec R, Luksa L, Jurkovic I, Kovac N, Mihaljevic S, et al. Safety and efficacy of
551 fluvoxamine in COVID-19 ICU patients: An open label, prospective cohort trial with matched controls.
552 *British journal of clinical pharmacology*. 2021.
- 553 25. Lenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE, et al. Fluvoxamine vs placebo
554 and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. *Jama*.
555 2020;324(22):2292-300.
- 556 26. Reis G, dos Santos Moreira-Silva EA, Silva DCM, Thabane L, Milagres AC, Ferreira TS, et al. Effect
557 of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with
558 COVID-19: the TOGETHER randomised, platform clinical trial. *The Lancet Global Health*. 2022;10(1):e42-
559 e51.
- 560 27. Azkur AK, Akdis M, Azkur D, Sokolowska M, van de Veen W, Brüggemann MC, et al. Immune
561 response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. *Allergy*.
562 2020;75(7):1564-81.
- 563 28. Cañas-González B, Fernández-Nistal A, Ramírez JM, Martínez-Fernández V. Influence of Stress
564 and Depression on the Immune System in Patients Evaluated in an Anti-aging Unit. *Frontiers in*
565 *psychology*. 2020;11:1844.
- 566 29. Dubovický M, Császár E, Melicherčíková K, Kuniaková M, Račková L. Modulation of microglial
567 function by the antidepressant drug venlafaxine. *Interdisciplinary toxicology*. 2014;7(4):201-7.
- 568 30. Ohgi Y, Futamura T, Kikuchi T, Hashimoto K. Effects of antidepressants on alternations in serum
569 cytokines and depressive-like behavior in mice after lipopolysaccharide administration. *Pharmacology,*
570 *biochemistry, and behavior*. 2013;103(4):853-9.
- 571 31. Hashimoto Y, Suzuki T, Hashimoto K. Mechanisms of action of fluvoxamine for COVID-19: a
572 historical review. *Molecular Psychiatry*. 2022.
- 573 32. Pashaei Y. Drug repurposing of selective serotonin reuptake inhibitors: Could these drugs help
574 fight COVID-19 and save lives? *Journal of clinical neuroscience : official journal of the Neurosurgical*
575 *Society of Australasia*. 2021;88:163-72.
- 576 33. Katoh N, Soga F, Nara T, Tamagawa-Mineoka R, Nin M, Kotani H, et al. Effect of serotonin on the
577 differentiation of human monocytes into dendritic cells. *Clinical and experimental immunology*.
578 2006;146(2):354-61.
- 579 34. Lang R, Patel D, Morris JJ, Rutschman RL, Murray PJ. Shaping gene expression in activated and
580 resting primary macrophages by IL-10. *Journal of immunology (Baltimore, Md : 1950)*.
581 2002;169(5):2253-63.
- 582 35. Arzt E, Costas M, Finkielman S, Nahmod VE. Serotonin inhibition of tumor necrosis factor-alpha
583 synthesis by human monocytes. *Life sciences*. 1991;48(26):2557-62.

- 584 36. Kubera M, Kenis G, Bosmans E, Scharpé S, Maes M. Effects of serotonin and serotonergic
585 agonists and antagonists on the production of interferon-gamma and interleukin-10.
586 *Neuropsychopharmacology* : official publication of the American College of Neuropsychopharmacology.
587 2000;23(1):89-98.
- 588 37. Adnot S, Houssaini A, Abid S, Marcos E, Amsellem V. Serotonin transporter and serotonin
589 receptors. *Handbook of experimental pharmacology*. 2013;218:365-80.
- 590 38. Ménard G, Turmel V, Bissonnette EY. Serotonin modulates the cytokine network in the lung:
591 involvement of prostaglandin E2. *Clinical and experimental immunology*. 2007;150(2):340-8.
- 592 39. Kornhuber J, Tripal P, Reichel M, Mühle C, Rhein C, Muehlbacher M, et al. Functional Inhibitors
593 of Acid Sphingomyelinase (FIASMs): a novel pharmacological group of drugs with broad clinical
594 applications. *Cellular physiology and biochemistry : international journal of experimental cellular*
595 *physiology, biochemistry, and pharmacology*. 2010;26(1):9-20.
- 596 40. Gulbins A, Schumacher F, Becker KA, Wilker B, Soddemann M, Boldrin F, et al. Antidepressants
597 act by inducing autophagy controlled by sphingomyelin-ceramide. *Mol Psychiatry*. 2018;23(12):2324-46.
- 598 41. Carpinteiro A, Edwards MJ, Hoffmann M, Kochs G, Gripp B, Weigang S, et al. Pharmacological
599 Inhibition of Acid Sphingomyelinase Prevents Uptake of SARS-CoV-2 by Epithelial Cells. *Cell reports*
600 *Medicine*. 2020;1(8):100142.
- 601 42. Hoertel N, Sánchez-Rico M, Vernet R, Jannot AS, Neuraz A, Blanco C, et al. Observational Study
602 of Chlorpromazine in Hospitalized Patients with COVID-19. *Clinical drug investigation*. 2021;41(3):221-
603 33.
- 604 43. Friesland M, Mingorance L, Chung J, Chisari FV, Gastaminza P. Sigma-1 receptor regulates early
605 steps of viral RNA replication at the onset of hepatitis C virus infection. *Journal of virology*.
606 2013;87(11):6377-90.
- 607 44. Vasallo C, Gastaminza P. Cellular stress responses in hepatitis C virus infection: Mastering a two-
608 edged sword. *Virus research*. 2015;209:100-17.
- 609 45. Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, et al. A SARS-CoV-2 protein
610 interaction map reveals targets for drug repurposing. *Nature*. 2020;583(7816):459-68.
- 611 46. Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate
612 Ca(2+) signaling and cell survival. *Cell*. 2007;131(3):596-610.
- 613 47. Hayashi T, Tsai SY, Mori T, Fujimoto M, Su TP. Targeting ligand-operated chaperone sigma-1
614 receptors in the treatment of neuropsychiatric disorders. *Expert opinion on therapeutic targets*.
615 2011;15(5):557-77.
- 616 48. Rosen DA, Seki SM, Fernández-Castañeda A, Beiter RM, Eccles JD, Woodfolk JA, et al.
617 Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and
618 sepsis. *Science translational medicine*. 2019;11(478).
- 619 49. Anderson GM. Fluvoxamine, melatonin and COVID-19. *Psychopharmacology*. 2021;238(2):611.
- 620 50. Sukhatme VP, Reiersen AM, Vayttaden SJ, Sukhatme VV. Fluvoxamine: A Review of Its
621 Mechanism of Action and Its Role in COVID-19. *Frontiers in pharmacology*. 2021;12:652688.
- 622 51. Zhang R, Wang X, Ni L, Di X, Ma B, Niu S, et al. COVID-19: Melatonin as a potential adjuvant
623 treatment. *Life sciences*. 2020;250:117583.
- 624 52. Bainum TB, Fike DS, Mechelay D, Haase KK. Effect of Abrupt Discontinuation of Antidepressants
625 in Critically Ill Hospitalized Adults. *Pharmacotherapy*. 2017;37(10):1231-40.
- 626 53. Kelly JM, Rubinfeld GD, Masson N, Min A, Adhikari NKJ. Using Selective Serotonin Reuptake
627 Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors in Critical Care: A Systematic Review of the
628 Evidence for Benefit or Harm. *Critical care medicine*. 2017;45(6):e607-e16.
- 629 54. Halperin D, Reber G. Influence of antidepressants on hemostasis. *Dialogues in clinical*
630 *neuroscience*. 2007;9(1):47-59.

631

632